Physiology‐based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab

Physiology‐based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab

Abstract Type I interferons contribute to the pathogenesis of several autoimmune disorders, including systemic lupus erythematosus (SLE), systemic sclerosis, cutaneous lupus erythematosus, and myositis. Anifrolumab is a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (I...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pradeep Sharma, David W. Boulton, Lynn N. Bertagnolli, Weifeng Tang
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.13245
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Recalcitrant Dermatomyositis Treated With Anifrolumab
by: Shivang Chaudhary, et al.
Published: (2025-01-01)

Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome
by: Ryan Bonaventure Soares, et al.
Published: (2025-01-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01)

Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus
by: E. V. Bolotova, et al.
Published: (2025-03-01)

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01)

Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies
by: Morris Muliaditan, et al.
Published: (2025-12-01)

Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS
by: Wei Lu, et al.
Published: (2024-12-01)

The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus
by: Fulvia Ceccarelli, et al.
Published: (2025-07-01)

Hypertrophic lupus erythematosus hypertrophic lichen planus overlap responding to acitretin and anifrolumab
by: Roxana A. Hojjatie, BS, et al.
Published: (2025-05-01)

Tissue distribution pharmacokinetics of intrathecal U1 adaptor oligonucleotide in mice
by: Medha Satti, et al.
Published: (2025-01-01)

Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles of Zidovudine in Rats
by: Shah Purvin, et al.
Published: (2014-01-01)

Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues.
by: Darta Maija Zake, et al.
Published: (2021-01-01)

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry
by: Wei Chen, et al.
Published: (2019-01-01)

Tissue Distribution and Pharmacokinetic Characteristics of Aztreonam Based on Multi-Species PBPK Model
by: Xiao Ye, et al.
Published: (2025-06-01)

Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01)

Flare of bullous lupus erythematosus in patients treated with anifrolumab for discoid lupus erythematosus: 2 cases
by: Cécile Lesort, MD, et al.
Published: (2025-04-01)

Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus
by: Bishoy Abdelmalik, BS, et al.
Published: (2025-01-01)

Can Dermoscopy Be a Useful Follow-Up Tool in Patients with Discoid Lupus Treated with Anifrolumab?
by: Francesca Ambrogio, et al.
Published: (2025-02-01)

Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
by: Monica E. Susilo, et al.
Published: (2025-04-01)

Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs
by: Sara Bettonte, et al.
Published: (2024-05-01)

Determination of Epimedin B in Rat Plasma and Tissue by LC-MS/MS: Application in Pharmacokinetic and Tissue Distribution Studies
by: Qianru Feng, et al.
Published: (2017-01-01)

Development of a Physiologically Based Pharmacokinetic Model for Nitrofurantoin in Rabbits, Rats, and Humans
by: Raju Prasad Sharma, et al.
Published: (2023-08-01)

Pharmacokinetics and Tissue Distribution of Palmatine after Single Intramuscular Injection in Partridge Shank Chickens
by: Chaoxi Chen, et al.
Published: (2025-07-01)

Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS
by: Yuzhe Cheng, et al.
Published: (2025-07-01)

Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report
by: Abdullah Ramadhan, et al.
Published: (2025-06-01)

WCN24-420 SAFETY AND EFFICACY OF ANIFROLUMAB IN IMMUNE COMPLEX AND APOL-1 ASSOCIATED LUPUS PODOCYTOPATHY
by: James Tumlin, et al.
Published: (2024-04-01)

Adjunctive anifrolumab for recalcitrant discoid lupus erythematosus in the setting of systemic lupus erythematosus: A case report
by: Gabriela Soto-Canetti, MPH, et al.
Published: (2025-06-01)

Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term
by: Felix Stader, et al.
Published: (2025-04-01)

A physiologically-based pharmacokinetic model for the antibiotic ertapenem
by: Michele L. Joyner, et al.
Published: (2015-09-01)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
by: Shufang Liu, et al.
Published: (2023-12-01)

Predicting Pharmacokinetics of Active Constituents in <i>Spatholobi caulis</i> by Using Physiologically Based Pharmacokinetic Models
by: Xiaoyan Liu, et al.
Published: (2024-12-01)

Measurement of Pharmacokinetics and Tissue Distribution of Four Compounds from Nauclea officinalis in Rat Plasma and Tissues through HPLC-MS/MS
by: Yuhuang Wu, et al.
Published: (2022-01-01)

Rapid resolution of fever and panniculitis after anifrolumab in a patient with systemic lupus erythematosus refractory to standard immunosuppression
by: Shunichiro Hanai, et al.
Published: (2025-08-01)

Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction
by: Ryota Sato, et al.
Published: (2025-07-01)

Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling
by: Stephan Schaller, et al.
Published: (2024-12-01)

Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults
by: Craig M. Comisar, et al.
Published: (2025-08-01)

[Translated article] Anifrolumab for the Treatment of Refractory Cutaneous Lupus Erythematosus: A Spanish Clinical Practice-Based Multicenter Study
by: D. Martín-Torregrosa, et al.
Published: (2025-05-01)

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi‐physiologic population pharmacokinetic approach
by: Juyoung Khwarg, et al.
Published: (2024-12-01)

Pharmacokinetics and brain tissue distribution of Gastrodia elata extract in normal and cerebral ischemic rats: a comparative study
by: Ji Shao, et al.
Published: (2025-07-01)

Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice Using a Validated Liquid Chromatography–Tandem Mass Spectrometry Method
by: Minyeong Pang, et al.
Published: (2025-01-01)